Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024

Rhea-AI Summary

Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's President and CEO, Nick Colangelo, along with CFO Joe Mara, will engage in a fireside chat on Friday, September 6, 2024, at 1:05 p.m. ET.

This presentation offers investors and interested parties an opportunity to gain insights into Vericel's operations, strategies, and market position. The event will be accessible via webcast on the Investor Relations section of Vericel's website, allowing for widespread viewing and potential increased investor engagement.

CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) --  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22^nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:

Eric Burns

ir@vcel.com

+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com 

FAQ

When is Vericel (VCEL) presenting at the Morgan Stanley Global Healthcare Conference?

Vericel (VCEL) is presenting at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024, at 1:05 p.m. ET.

Who will be representing Vericel (VCEL) at the Morgan Stanley conference?

Nick Colangelo, President and CEO, and Joe Mara, CFO, will be representing Vericel (VCEL) at the Morgan Stanley conference.

How can I watch Vericel's (VCEL) presentation at the Morgan Stanley conference?

You can watch Vericel's (VCEL) presentation via webcast on the Investor Relations section of the Vericel website at http://investors.vcel.com.

What markets does Vericel (VCEL) specialize in?

Vericel (VCEL) specializes in advanced therapies for the sports medicine and severe burn care markets.